Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Mongodb Inc (MDB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Mongodb Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.64 (market cap $29.60B), while Mongodb Inc trades at $442.75 (market cap $35.32B). The key difference: Mongodb Inc is the larger of the two by market cap, and Mongodb Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | MDB | |
|---|---|---|
Market Cap | $29.60B | $35.32B |
Sector | Health | Technology |
52-Week High | $491.22 | $440.25 |
52-Week Low | $205.48 | $204.37 |
Enterprise Value | $27.56B | $32.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
MongoDB (MDB) trades at $416.67, up 4.48% in the last session, with a bullish technical setup per moving averages and ADX. Revenue growth is robust, reaching $2.01B in 2025, though the company remains unprofitable with a net margin of -1.12%. Recent earnings beats and strong analyst sentiment, with 82% buy ratings, support optimism. The stock is near its pivot point of $412, with resistance at $428.
Outlook: MDB's growth trajectory and AI-driven demand present upside, but profitability concerns and high valuation multiples (P/S 13.73) pose risks. Investors should weigh revenue momentum against persistent losses and competitive pressures in the database software market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →
